Le Lézard
Classified in: Health
Subjects: RCL, PSF, CFG

Information Update - Health Canada warns about hand sanitizers that may pose health risks


OTTAWA, ON, Dec. 21, 2021 /CNW/ - Health Canada is advising Canadians that the following hand sanitizers are being recalled because they may pose health risks. For more information, including what Canadians should do, visit the online safety alert.

Health Canada maintains this list of hand sanitizers that may pose health risks, so that Canadians can easily identify products they may have purchased and take appropriate action. Canadians are encouraged to check it regularly for updates.

Product

Health Risk

Company

NPN or DIN

Lot Number

Expiry Date

Action Taken

Sani-Derm

May contain unacceptable ingredient, ethyl acetate

Laboratoires Choisy (Kersia Group)

No NPN or DIN on the label

All Lots

  • January 2022
  • February 2022
  • March 2022
  • April 2022

Product recalled by company

Stay connected with Health Canada and receive the latest advisories and product recalls.

Également disponible en français

SOURCE Health Canada


These press releases may also interest you

at 06:03
THE IAMStm BRAND LAUNCHES ONLINE KITTEN AND PUPPY HUBS TO EMPOWER PET PARENTS IN CANADA WITH EXPERT INFORMATION
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
TELUS Health enables health data interoperability in Nova Scotia
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
Digital Healthcare Market Size to reach $836.10 billion by 2031, growing at a CAGR of 21%, says Coherent Market Insights
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Sectra publishes Annual Report and Sustainability Report for 2023/2024
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Launch of Phase 3 clinical trial with Nefecon in Japan
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

More news about Health...


News published on and distributed by: